https://www.hcplive.com/view/empagliflozin-provides-consistent-benefit-in-hfref-regardless-of-diuretic-use
Data from the EMPEROR-Reduced trial provide insight into the effects of empagliflozin in patients with heart failure with reduced ejection fraction based on baseline diuretic use from the phase 3 trial.
Create an account or login to join the discussion